Physician profile
Michael R Rupp
NPI 1720091143
$3,041.47
in general payments reported to CMS, 2019-2025
22 companies · $367 in 2025
The $367 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $321 · 2021: $675 · 2022: $540 · 2023: $473 · 2024: $364 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,204.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $767.17 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $439.08 | 2019-2024 | Dyanavel Xr |
| Corium, LLC | $384.13 | 2021-2024 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $208.60 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $178.72 | 2019-2024 | Bexsero, Rotarix, Pediarix |
| Takeda Pharmaceuticals U.S.A., INC. | $121.84 | 2021-2022 | |
| Neos Therapeutics, LP | $119.40 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $105.73 | 2021-2024 | Qelbree, Qelbree |
| Cranial Technologies, INC | $90.81 | 2022-2025 | Doc Band |
| Sanofi Pasteur INC. | $87.72 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $84.94 | 2020-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Pfizer INC. | $80.35 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $70.39 | 2025 | Jornay Pm |
| Genentech USA, INC. | $59.25 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $43.75 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $43.37 | 2020 | |
| Neuraxis, INC. | $41.06 | 2024 | |
| Shire North American Group INC | $38.47 | 2019 | |
| Eyevance Pharmaceuticals LLC | $22.93 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.77 | 2025 | |
| Krystal Biotech INC | $17.63 | 2024 | Vyjuvek |
| Seqirus USA INC | $16.36 | 2023 | Flucelvax Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rupp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.